Author:
Qiu Shengyang,Nikolaou Stella,Fiorentino Francesca,Rasheed Shahnawaz,Darzi Ara,Cunningham David,Tekkis Paris,Kontovounisios Christos
Funder
Royal Marsden NHS Foundation Trust
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Reference37 articles.
1. The Office of National Statistics (2017) Office for National Statistics, Cancer survival by stage at diagnosis for England.
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/nationalestimatesforpatientsfollowedupto2017
. Accessed 31 Jan 2019
2. National Institute of Health and Clinical Excellence (2015) Suspected cancer: recognition and referral. National Institute for Health and Care Excellence: Clinical Guidelines.
https://www.nice.org.uk/guidance/ng12
. Accessed 4 Feb 2019
3. Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248(19):6854–6861
4. Evers BM (2006) Neurotensin and growth of normal and neoplastic tissues. Peptides. 27(10):2424–2433.
https://doi.org/10.1016/j.peptides.2006.01.028
5. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M (1999) Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 80(3):448–454.
https://doi.org/10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献